Phase 3 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older.
• People with a new diagnosis of liver cancer (hepatocellular carcinoma) that has not yet been treated, confirmed by tissue sample or imaging, with at least one tumour that can be measured using standard imaging guidelines. A previous liver cancer treated with surgery or radiation is allowed, as long as it was at least 2 years before the current diagnosis.
• People whose cancer has been assessed by a specialist team panel as locally advanced and not suitable for surgical removal.
• People with a liver cirrhosis severity score of Child-Pugh B7 or higher, who are considered not suitable for intensive cancer drug treatment (confirm with trial site).
• People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out some daily activities, even if limited).
• People with adequate blood counts and organ function, as confirmed by testing.
• Sexually active male participants with a partner who could become pregnant must agree to use an accepted and effective form of contraception throughout the study period, as the study drug (Memantine) is known to be harmful to a developing baby.
• Female participants who could become pregnant must have a negative blood pregnancy test within 24 hours before starting treatment, and must agree to use an accepted and effective form of contraception throughout the study period.
• People who are willing and able to understand and sign a written consent form agreeing to take part.
• Men and women of any race, ethnic group, or sexual orientation are eligible for this study.

Who may not be able to join:

• People with a liver cirrhosis severity score classified as Child-Pugh A.
• People who are pregnant or currently breastfeeding.
• People with other existing illnesses or medical history that could interfere with safe participation or assessment in the study, as judged by the investigators.
• People with a life-threatening illness occurring at the same time.
• People who the medical team believes are unlikely to be able to follow the study requirements reliably.
• People who are already enrolled in another interventional clinical trial.
• People with active tuberculosis.
• People with serious heart or blood vessel conditions — such as significant heart disease, a heart attack, or stroke within the past 3 months, or unstable heart rhythm or unstable chest pain.
• People whose liver cancer is a specific rare type, including fibrolamellar HCC, sarcomatoid HCC, or a mixed liver and bile duct cancer.
• People with pain caused by their tumour that is not well controlled. People who are on pain medication must have been on a stable dose for at least 10 days before joining.
• People who have had a major surgical procedure, open biopsy, or serious physical injury within the 28 days before starting the study treatment.
• People with cancer that has spread to the brain or nervous system, where symptoms are present, untreated, or actively getting worse.
• People currently receiving other cancer treatments, with the exception of palliative radiation used for symptom relief, which is permitted during the study.

Important: Always verify eligibility with the trial site directly before applying.